Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bruno Lucidi leaves Karolinska

This article was originally published in Scrip

Executive Summary

Stockholm-based Karolinska Development has announced that CEO Bruno Lucidi has left the company, less than four months after his permanent appointment to the position. Mr Lucidi's departure has been chalked-up to a "difference of opinion" between the former CEO and the company's board or directors over the implementation of the company's strategy. He has been replaced by deputy CEO Terje Kalland until a new, permanent CEO can be appointed, the company said. Karolinska has begun a search for a permanent successor. Mr Lucidi is also stepping down as CEO for KDev Oncology and Karolinska Development's portfolio companies Aprea and Akinion Pharmaceuticals.

You may also be interested in...

Femtech Presents Enticing Market Opportunity

A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.

Execs On The Move, Sep 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Snapshot: September Highlights

A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts